The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ACADEMIA
High Hopes for Sanofi’s Enjaymo as Japan’s First CAD Therapy: Osaka University Professor
Sanofi’s Enjaymo (sutimlimab), which grabbed regulatory approval in June as Japan’s first cold agglutinin disease (CAD) drug, is highly promising as a first-line treatment, Osaka University Professor Junichi Nishimura said on August 3. Prof. Nishimura, associated with the university’s Department…
To read the full story
Related Article
- Japan’s First CAD Therapy, Enjaymo, Now Available: Sanofi
September 9, 2022
ACADEMIA
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…